Search
Now showing items 1-10 of 29
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.
(2018-09-04)
BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0-5-year and 5-10-year ...
Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews.
(2018-08)
PURPOSE: Uptake of preventive therapy for women at increased breast cancer risk in England is unknown following the introduction of UK clinical guidelines in 2013. Preventive therapy could create socioeconomic inequalities ...
Lifestyle behaviours and health measures of women at increased risk of breast cancer taking chemoprevention.
(Lippincott, Williams & Wilkins, 2018-11-15)
Women at increased breast cancer (BC) risk are eligible for chemoprevention. Healthy lifestyles are potentially important for these women to improve efficacy and minimise side effects of chemoprevention and reduce the risk ...
Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK.
(2018-01-25)
BACKGROUND: The differences between breast cancer risk factors in white British/Irish and Asian women attending screening in the UK are not well documented. METHODS: Between 2009-15 ethnicity and traditional breast cancer ...
The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.
(2018-09-03)
BACKGROUND: Observational studies have reported conflicting results on the impact of mammography service screening programmes on the advanced breast cancer rate (ABCR), a correlation that was firmly established in randomized ...
Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.
(2015)
INTRODUCTION: Letrozole, an aromatase inhibitor, is a commonly used neo-adjuvant drug to treat hormone-sensitive breast cancer. There have been a few cases of aromatase inhibitor induced vasculitis but the first case of ...
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
(Springer US, 2019-04-30)
PURPOSE:
EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we ...
